In summary, we found that in ErbB2-overexpressing breast cancer cells the ErbB2/Grb2 interaction leads to the direct activation of RAS which, in turn, mediates via interaction with p110α the p-AKT rebound in response to an incomplete blockade of ErbB2. Here, GRB2 is linked to breast cancer.